Skip to content

Safety of combination therapy of HAL and repeptive trancranial magnetic stimulation

Safety of combination therapy of robot suit HAL and repeptive transcranial magnetic stimulation for freezing gait of Parkinson disease

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs032220409
Enrollment
5
Registered
2022-10-25
Start date
2022-10-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinsonian Disease freezing gait

Interventions

repeptive transcranial magnetic stimulation: 20 minutes once, 1 times a week,total 3 weeks robot suit HAL: 60 minutes once, 3-4 times a week,total 3 weeks

Sponsors

YAMANAKA Yoshitaka
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient who meet all of the following conditinons are targeted 1) Yahr classification: 2-4 Parkinson syndrome patients 2) Patients whose freezing gait do not improve even after using a sufficient amount of anti-Parkinson's disease drug 3)Patients aged over 20 under 80 at the time of informed consent 4)Patients who can consent to appropriate contraception for the duration of the study 5)Patients who have received sufficient explanation in participating in this study, and who have obtained written consent at their own free will with sufficient understanding.

Exclusion criteria

Exclusion criteria: patient who meet any of the following condition are not eligible 1) Patients who received a new start or increased dose of anti-PD drug within 12 weeks 2) Patients with other diseases such as occupied lesions on the head image 3) Cases in which rTMS is contraindicated in the guidelines on the safety of magnetic stimulation (2019 edition) 4)Patient who are considered difficult to train with HAL 5) Patients who are pregnant, may become pregnant, within 28 days after giving birth, or are breastfeeding 6) In addition, patients who are judged by the investigator or the investigator to be inappropriate for conducting this study safely.

Design outcomes

Primary

MeasureTime frame
frequency of adverse event 1) serious adverse event 2) Previously reported advers events in HAL (myalgia, contact dermatitis, abrasions, back pain, falls, contusions, limb pain, arthralgia) 3) Previously reported advers events in rTMS (scalp pain, irritation pain, facial discomfort, neck pain, stiff shoulders, headache, epilepsy, dizziness exacerbation) 4) Unexpected adverse event

Secondary

MeasureTime frame
1.MDS- UPDRS 3rd score change 2. Freezing of gait questionnaire 3. Change in Timed up and go test 4. 10m change in walking time

Contacts

Public ContactYoshitaka YAMANAKA

Chiba University Hospital

y-yama@hospital.chiba-u.jp+81-473126765

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026